This finding is in line with other recent findings describing acquired MET amplification as a potential resistance mechanism to NTRK inhibitor therapy, similar to that described for targeted EGFR inhibitor therapy in NSCLC patients24,25. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.